IJSTR

International Journal of Scientific & Technology Research

Home About Us Scope Editorial Board Blog/Latest News Contact Us
0.2
2019CiteScore
 
10th percentile
Powered by  Scopus
Scopus coverage:
Nov 2018 to May 2020

CALL FOR PAPERS
AUTHORS
DOWNLOADS
CONTACT

IJSTR >> Volume 9 - Issue 1, January 2020 Edition



International Journal of Scientific & Technology Research  
International Journal of Scientific & Technology Research

Website: http://www.ijstr.org

ISSN 2277-8616



Development Of RP-HPLC Procedure And Forced Stability Studies For Lotion Formulations Of Tazarotene And Halobetasol

[Full Text]

 

AUTHOR(S)

T. Sravanthi, N. Madhavi

 

KEYWORDS

Tazarotene, Halobetasol, Topical lotion, Analysis, Stability study

 

ABSTRACT

In the current research, an isocratic, novel RP-HPLC method was developed for quantifying tazarotene and halobetasol simultaneously. The HPLC method was optimized using the Waters C18 column (150 mm × 4.5 mm; 5 µm), employing simple isocratic method. Experimental parameters were standardized, including mobile phase, pH, wavelength detection and flow rate. The method has been validated in conformance with the guideline frame of ICH. This method was apt for determination of tazarotene and halobetasol in bulk and lotion formulation samples with suitable precision (relative standard deviation: 0.135-0.189% for tazarotene and 0.229-0.472% for halobetasol), accuracy (recovery: 98.66-100.70% for tazarotene and 98.21-100.09% for halobetasol) and linearity (2.25-11.25 μg/ml for tazarotene and 0.5-2.5 µg/ml for halobestol). This method has a better ability in the routine analysis of tazarotene and halobetasol in bulk and lotion formulations. The present method was successfully applied to lotion formulations for assessment of stability of tazarotene and halobetasol under basic, acidic, oxidative, photolytic and thermal conditions.

 

REFERENCES

[1] Tazoretene. Drug bank, accessed on November 2019. Available at: https://www.drugbank.ca/drugs/DB00799
[2] Tazoretene. Pubchem, U.S. National Library of Medicine, accessed on November 2019. Available at: https://pubchem.ncbi.nlm.nih.gov/compound/Tazarotene
[3] G. Weindl, A. Roeder, M. Schäfer-Korting, M. Schaller and H.C. Korting, “Receptor-selective retinoids for psoriasis: focus on tazarotene”, Am. J. Clin. Dermatol, vol. 7, no. 2, pp. 85-97, 2006.
[4] S. Ogden, M. Samuel and C.E. Griffiths, “A review of tazarotene in the treatment of photodamaged skin”, Clin. Interv. Aging, vol. 3, no. 1, pp. 71–76, 2008.
[5] E. Tanghetti, M. Lebwohl and L.S. Gold, “Tazarotene Revisited: Safety and efficacy in plaque psoriasis and its emerging role in treatment strategy”, J. Drugs Dermatol, vol. 17, no. 12, pp. 1280-1287, 2018.
[6] S. Gregoriou, E. Kritsotaki, A. Katoulis and D. Rigopoulos, “Use of tazarotene foam for the treatment of acne vulgaris”, Clin. Cosmet. Investig. Dermatol, vol. 7, pp. 165–170, 2014.
[7] G. Latter, J.E. Grice, Y. Mohammed, M.S. Roberts and H.A.E. Benson, “Targeted topical delivery of retinoids in the management of acne vulgaris: Current formulations and novel delivery systems”, Pharmaceutics, vol. 11, no. 10, pp. pii: E490, 2019.
[8] Halobetasol Cream. StatPearls [Internet]. Treasure Island (FL), StatPearls Publishing, 2019. Accessed on November 2019. Available at:

https://www.ncbi.nlm.nih.gov/books/NBK544234/
[9] Halobestol. Pubchem, U.S. National Library of
Medicine, accessed on November 2019.
Available at: https://pubchem.ncbi.nlm.nih.gov/compound/Halobetasol
[10] F.A. Kerdel, Z.D. Draelos, S.K. Tyring, T. Lin and R. Pillai, “A phase 2, multicenter, double-blind, randomized, vehicle-controlled clinical study to compare the safety and efficacy of a halobetasol propionate 0.01% lotion and halobetasol propionate 0.05% cream in the treatment of plaque psoriasis”, J. Dermatolog. Treat, vol. 30, no. 4, pp. 333-339, 2019.
[11] L.J. Green, F.A. Kerdel, F.E. Cook-Bolden, J. Bagel, T. Lin, G. Martin, R. Pillai, R. Israel and T. Ramakrishna, “Safety and Efficacy of a Once-Daily Halobetasol propionate 0.01% lotion in the treatment of moderate-to-severe plaque psoriasis: Results of two phase 3 randomized controlled trials”, J. Drugs Dermatol, vol. 17, no. 10, pp. 1062-1069, 2018.
[12] Duobrii Approval History. Drugs.com, Accessed on November 2019. Available at: https://www.drugs.com/history/duobrii.html
[13] N.D. Bhatia, D.M. Pariser and L. Kircik, “Safety and efficacy of a halobetasol 0.01%/tazarotene 0.045% fixed combination lotion in the treatment of moderate-to-severe plaque psoriasis: A comparison with halobetasol propionate 0.05% Cream”, J. Clin. Aesthet. Dermatol, vol. 11, no. 11, pp. 15–19, 2018.
[14] M.G. Lebwohl, J.L. Sugarman, L.S. Gold, T. Lin and R. Israel, “Efficacy, safety, and tolerability of a halobetasol 0.01% tazarotene 0.045% fixed combination in the treatment of severe localized plaque psoriasis: Post hoc analysis of two phase III randomized controlled trials”, J. Drugs Dermatol, vol. 18, no. 10, pp. 1012-1018, 2019.
[15] International conference on the harmonization. ICH harmonized tripartite guideline. Stability testing of new drug substances and products Q1A (R2), Geneva, Switzerland, 2003.
[16] International conference on the harmonization. ICH harmonized tripartite guideline. Validation of analytical procedures: Text and methodology Q2 (R1), Geneva, Switzerland, 2005.
[17] FDA, Reviewer Guidance: Validation of chromatographic methods, United States Food and Drug Administration, Silver Spring, MD, USA, August 2018, https://www.fda.gov/downloads/drugs/guidances/ucm134409.pdf.
[18] G. A. Shabir, “Validation of high performance liquid chromatography methods for pharmaceutical analysis. Understanding the difference and similarities between validation requirements of the US Food and Drug Administration, the US Pharmacopoeia and the International Conference on Harmonization,” J. Chromatogr. A, vol. 987, no. 1-2, pp. 56–66, 2003.